跳至主要内容
临床试验/CTRI/2022/05/042752
CTRI/2022/05/042752招募中未知

Efficacy and safety of Twin Precision treatment in patients with hypertension- a multicentric, open-label, randomised controlled trial - TPT-4

TWINS DIGITAL SERVICES INDIA PRIVATE LIMITED0 个研究点目标入组 0 人开始时间: 待定最近更新:

试验速览

阶段
未知
状态
招募中
发起方

研究概览

简要总结

暂无简介。

研究设计

研究类型
Interventional

入排标准

入选标准

  • Patients with diagnosis of primary hypertension (either adequately controlled or inadequately controlled with blood pressure = 180/110 mm Hg); both treatment naive & on treatment (includes monotherapy or multiple drugs)
  • Age 18 years and above
  • Of either gender
  • Willing to follow study specific activities and able to handle smartphone

排除标准

  • Key exclusion criteria
  • Uncontrolled hypertension ( > 180/110 mm of Hg)
  • H/o hypertensive emergency requiring admission / Resistant Hypertension
  • Diabetes mellitus
  • Major Gastrointestinal diseases such as Inflammatory bowel disease, irritable bowel syndrome that can interfere with dietary intervention
  • Use of contraindicated drugs such as antacids of magnesium, calcium, steroids, lithium, anti-migraine drugs, phenytoin, anti-psychotics (SSRI, SNRI, and TCA), immuno-modulators, any narcotic drugs, and oral contraceptives.
  • Having received any investigational drug or device within 30 days prior to entry into the study
  • Poor compliance during screening or run in.
  • Autoimmune disorders and Connective tissue disorders
  • Total bilirubin of > 2 mg/dL or aspartate aminotransferase (AST) and alanine aminotransferase (ALT) 5 times the upper limit of normal range
  • Pregnant or planning to conceive in the next 3 years or breastfeeding
  • Psychiatric illness such as psychosis, manic depressive illness, alcohol or drug dependence .
  • Consumption of >14 alcoholic beverages per week (for women) and > 21 for men
  • Any other condition or illness which the investigator feels would make the patient ineligible or make the patient difficult to participate in the study
  • Any major cardiovascular event in the last 6 months (such as MI, stroke, TIA)
  • Hypertensive Retinopathy (grade 3 and above)
  • Weight loss more than 5% in 3 months
  • Arm circumference too large or small to allow accurate BP measurement with available devices
  • Special dietary requirements,or medications that would affect blood pressure (other than antihypertensive drugs) or nutrient metabolism
  • Unwilling or inability to modify current diet
  • Hypercalcemia ( > 10.5 mg/dl) and Hyperkalemia.( >5.5 mmol/l)
  • Known Malignant cases < 5 years
  • Anemia (Hb < 8 gm)
  • Heart failure with EF < 40%

研究者

发起方
TWINS DIGITAL SERVICES INDIA PRIVATE LIMITED

相似试验